| |
To date, no efficient treatment existed for patients with advanced hepatocellular carcinoma. In a study led by the Hospital Clínic, it is demonstrated that Sorafenib improves the survival of these patients in three months, what consolidates this drug as the first therapeutic strategy with a positive impact on life expectancy. The results of this trial have already modified the recommendations of international guidelines for the treatment of liver cancer. |
|